MedTrace Logo

Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy

NCT00911911 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2026-03-13

No results posted yet for this study

Summary

The scope of the trial is to identify proteomic signatures correlated with tumor response to neo-adjuvant chemotherapy.

Conditions

Interventions

PROCEDURE

Blood sampling

Taken at different times : inclusion, at the cycle 4 and at the cycle 6 during the neoadjuvant chemotherapy

PROCEDURE

BIOPSY

Biopsy at the moment of inclusion, before neoadjuvant chemotherapy

PROCEDURE

SURGERY

Surgery after neoadjuvant chemotherapy

Sponsors & Collaborators

  • Centre Oscar Lambret

    lead OTHER

Principal Investigators

  • BONNETERRE Jacques, MD, PhD · Centre Oscar Lambret

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-22
Primary Completion
2009-01-31
Completion
2012-01-16

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00911911 on ClinicalTrials.gov